A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals

BACKGROUND: Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascular risk in persons with HIV-1 infection. METHODS: A randomized, 12 week, open-label, comparative study of the impact on lipids of continuation of abacavir/lamivudine (ABC/3TC) plus efavirenz (EFV) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Moyle, Graeme J., Orkin, Chloe, Fisher, Martin, Dhar, Jyoti, Anderson, Jane, Wilkins, Edmund, Ewan, Jacqueline, Ebrahimi, Ramin, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319732/
https://www.ncbi.nlm.nih.gov/pubmed/25658097
http://dx.doi.org/10.1371/journal.pone.0116297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319732/
https://www.ncbi.nlm.nih.gov/pubmed/25658097
http://dx.doi.org/10.1371/journal.pone.0116297

Ejemplares similares